Ra, can be released from its original vector, leave the target tissue, relocate and could be deposited in non-target organs. We did not observe complete progeny wash-out from its original target tissues in our model. This indicates strong dependence of the progeny hot atom fate after its release from the original radiopharmaceutical preparation on multiple factors, like their internalization and retention in cells, cell membranes, extracellular matrices, protein binding, etc. We hypothesize, that also the primary tumour or metastasis size, their metabolic activity may significantly influence progeny fate in vivo, directly impacting the dose delivered to non-target tissues and organs. Therefore a bottom-up approach should be followed and detailed pre-/clinical studies on the release and biodistribution of radioactive progeny originating from the chain alpha emitters should be preferably performed.
Keyphrases
- mouse model
- rheumatoid arthritis
- gene expression
- induced apoptosis
- cell therapy
- single cell
- ankylosing spondylitis
- stem cells
- small molecule
- molecular dynamics
- cell cycle arrest
- risk assessment
- mesenchymal stem cells
- high resolution
- binding protein
- cell death
- systemic sclerosis
- oxidative stress
- idiopathic pulmonary fibrosis
- protein protein
- light emitting